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The time-to-result for culture-based microorganism recovery and phenotypic
antimicrobial susceptibility testing necessitates initial use of empiric (frequently
broad-spectrum) antimicrobial therapy. If the empiric therapy is not optimal, this can
lead to adverse patient outcomes and contribute to increasing antibiotic resistance
in pathogens. New, more rapid technologies are emerging to meet this need. Many
of these are based on identifying resistance genes, rather than directly assaying
resistance phenotypes, and thus require interpretation to translate the genotype into
treatment recommendations. These interpretations, like other parts of clinical diagnostic
workflows, are likely to be increasingly automated in the future. We set out to evaluate
the two major approaches that could be amenable to automation pipelines: rules-based
methods and machine learning methods. The rules-based algorithm makes predictions
based upon current, curated knowledge of Enterobacteriaceae resistance genes. The
machine-learning algorithm predicts resistance and susceptibility based on a model built
from a training set of variably resistant isolates. As our test set, we used whole genome
sequence data from 78 clinical Enterobacteriaceae isolates, previously identified to
represent a variety of phenotypes, from fully-susceptible to pan-resistant strains for
the antibiotics tested. We tested three antibiotic resistance determinant databases for
their utility in identifying the complete resistome for each isolate. The predictions of
the rules-based and machine learning algorithms for these isolates were compared
to results of phenotype-based diagnostics. The rules based and machine-learning
predictions achieved agreement with standard-of-care phenotypic diagnostics of 89.0
and 90.3%, respectively, across twelve antibiotic agents from six major antibiotic
classes. Several sources of disagreement between the algorithms were identified. Novel
variants of known resistance factors and incomplete genome assembly confounded
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the rules-based algorithm, resulting in predictions based on gene family, rather than o
knowledge of the specific variant found. Low-frequency resistance caused errors in th
machine-learning algorithm because those genes were not seen or seen infrequentl
in the test set. We also identified an example of variability in the phenotype-base
results that led to disagreement with both genotype-based methods. Genotype-base
antimicrobial susceptibility testing shows great promise as a diagnostic tool, and w
outline specific research goals to further refine this methodology.
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INTRODUCTION
The spread of antibiotic resistance has become an urgent
threat to modern medicine’s control over bacterial infections. In
critically ill patients, it has been well established that the time
taken to administer an appropriate antibiotic agent inversely
correlates with improved patient outcomes (Kumar et al., 2006).
Unfortunately, definitive in vitro antibiotic susceptibility testing
(AST) results are not typically available until at least 2 days after
specimens arrive in the clinical laboratory (Didelot et al., 2012),
necessitating broad spectrum empiric antibiotic therapy.
Rapid antimicrobial resistance diagnostics could reduce the
time to treatment with the optimal antibiotic therapy for the
millions of patients infected with antibiotic resistant pathogens
each year (CDC, 2013). Increasing pressure to improve antibiotic
stewardship also favors the development of faster diagnostics
(Caliendo et al., 2013; Barlam et al., 2016)—reducing the
interval of diagnostic uncertainty will result in more judicious
antimicrobial use. The growth rate of infectious agents imposes
a limit on the speed with which phenotype-based AST can return
results, meaning that a new diagnostic paradigm is needed to
inform initial treatment.
Several diagnostic assays have emerged that rapidly identify
antibiotic resistance based on genotypic rather than phenotypic
information, including multiplex PCR and microarray assays
designed to identify resistance-specific markers (Pulido et al.,
2013; Kothari et al., 2014; Zumla et al., 2014). While these
techniques can be successful at detecting resistance determinants
mediated by specific enzymes, few of these methods can detect
resistance mediated by target mutation, such as fluoroquinolone
resistance (Pulido et al., 2013; Kothari et al., 2014; Zumla et al.,
2014), and accuracy decreases as additional genes are assayed
(Mancini et al., 2010).
Whole genome sequencing (WGS) has been proposed as
a complementary method for identifying antibiotic resistance
genes (Didelot et al., 2012; Bertelli and Greub, 2013; Zumla
et al., 2014). As this approach interrogates the entire genome
of each organism, WGS can identify the full set of known
resistance factors in an organism including target-mediated
resistance. WGS can also be used to identify new resistance
gene variants, and can contribute to identifying entirely novel
resistance gene families. Another advantage is that neither
the DNA preparation nor the resistance gene identification
steps increase in duration or cost as the number of antibiotics
evaluated increases. Pathogen WGS is also being evaluated for
other roles in clinical diagnostics, such as species identification
(Wilson et al., 2014) and assessment of strain relatedness (Snitkin
et al., 2012; Reuter et al., 2013), thereby affording the potential for
a single test to be used formultiple purposes. Several authors have
implemented WGS as a potential clinical diagnostic (Stoesser
et al., 2013; Gordon et al., 2014; Hasman et al., 2014; Leopold
et al., 2014), arguing that the time and cost of sequencing
will decrease to acceptable levels in the near future. As further
evidence of increasing interest in this technology, the United
States Food and Drug Administration (FDA) has recently issued
draft guidelines for diagnostic manufacturers seeking to develop
new devices for WGS based infectious disease diagnostics
(Sichtig, 2016).
Despite its potential benefits, any WGS-based diagnostic
still has several hurdles to overcome before it can become
a viable alternative to in vitro phenotypic tests. First, it is
currently slower and more expensive than traditional phenotypic
susceptibility testing. This limitation is likely to diminish
over time, as innovations in sequencing methodologies are
continually decreasing cost and assay duration (Feng et al., 2015;
Wetterstrand, 2016). Second, the genes relevant to antibiotic
resistance must be identified during the analysis phase, rather
than being directly selected by the technique. This increases
analysis time and introduces the potential that sequencing
or alignment errors introduce inaccuracies in resistance gene
identification.
Previous implementations of genotype-based diagnostics
have focused on identifying antibiotic resistance determinants,
without optimizing interpretation of the organism susceptibility
profile (Pulido et al., 2013; Stoesser et al., 2013; Gordon et al.,
2014; Hasman et al., 2014; Kothari et al., 2014; Zumla et al.,
2014). Simple gene identification can suggest what antibiotics
an infection may be resistant to, but they are inconclusive
about what treatments will indeed be active. The emergence
of transferrable resistance to last-resort drugs like colistin (Liu
et al., 2016) and the carbapenems (Yigit et al., 2001), both in
the context of already multidrug-resistant pathogens, virtually
guarantees the spread of nearly pan-resistant isolates. Accurate
identification of any antibiotic susceptibilities these isolates
may still have is especially important. A true genotype-based
antibiotic susceptibility prediction (GBASP) algorithm that could
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more rapidly provide all of the information given by current
phenotypic AST methods would need to be able to provide this
critical susceptibility information.
Providing susceptibility information that can directly
inform treatment recommendations requires an additional
layer of interpretation for GBASP than is found in current
implementations of genotype-based diagnostics. It is critical
to minimize errors in this interpretation step, as the results of
this step will directly affect treatment decisions. The presence
or absence of specific resistance genes must be associated with
resistance (and susceptibility) to particular antibiotics, and
then the resistance profiles for all genes in a particular isolate
must be added together to provide the predicted susceptibility
profile for that organism. The case of the β-lactamases in the
Enterobacteriaceae highlights the potential difficulties of this
interpretation. Single Enterobacteriaceae isolates may carry
multiple β-lactamase genes, and the resistance provided by
each of these resistance genes against the diverse class of β-
lactam drugs (i.e., penicillins, cephalosporins, cephamycins, and
carbapenems) is determined not just by the family to which
those genes belong, but in some cases by specific amino acid
substitutions (Bush and Jacoby, 2010).
In this study we evaluated multiple analytical approaches to
interpreting WGS GBASP as an alternative to phenotypic AST.
We first compared the performance of three curated antibiotic
resistance sequence databases in identifying the genes important
for resistance. Next, for the critical step of translating resistance
gene identifications into resistance and susceptibility predictions,
we compared a rules-based algorithm to a machine learning
approach. In general, rules-based algorithms should be equally
successful whether they are applied to a small or large set of
pathogens and errors should be relatively easy to detect and fix,
but they can only account for known factors that contribute to
resistance. Machine learning algorithms should be able to deduce
patterns from gene data regardless of whether those patterns are
already known to the field, but they require large training sets to
be effective and errors may be difficult to interpret. We therefore
chose to implement both algorithms and compare their results.
Our rules-based algorithm used a hard-coded resistance profile
for each resistance gene identified, based on existing curated
knowledge of resistance in the Enterobacteriaceae, while our
machine learning approach treats all resistance genes equally and
makes predictions based on algorithmically-deduced patterns in
the data.
We applied this pipeline to predict the resistance profiles of 78
previously characterized genome-sequenced Enterobacteriaceae
isolates (Pesesky et al., 2015) to 12 antibiotics. To best evaluate
the predicted profiles as a clinical metric, we compared the
results to the categorical interpretation of in vitro susceptibility
testing determined by Kirby Bauer Disk Diffusion (CLSI, 2015),
the method currently employed by the clinical microbiology
laboratory of Barnes Jewish Hospital, St. Louis, MO. For each
antibiotic class, we then assessed the strengths and weaknesses of
each predictive algorithm. Our goal was to determine the current
most effective implementation of automated interpretation for
GBASP, how close that implementation came to standards
necessary for clinical use, and to identify specific knowledge
gaps needed to improve future iterations of this diagnostic
approach.
METHODS AND MATERIALS
Sample Selection, Phenotype
Determination, and Sequencing
Isolates were retrieved from existing strain banks in Pakistan
Railway General Hospital, Rawalpindi, Pakistan; the Pakistan
Institute of Medical Sciences in Islamabad, Pakistan; or Barnes
Jewish Hospital/Washington University (WU) School of
Medicine in Saint Louis, Missouri, U.S.A. Isolate phenotypes
and draft genome sequences were determined in previous
work (Pesesky et al., 2015) (BioProject ID PRJNA261540).
Briefly, antibiotic susceptibility phenotypes were determined
using Kirby-Bauer disk diffusion according to Clinical and
Laboratory Standards Institute guidelines and interpretive
criteria (CLSI, 2015). Twelve antibiotics were tested: ampicillin
(AMP), cefazolin (CFZ), cefotetan (CTT), ceftazidime (CAZ),
ceftriaxone (CRO), cefepime (FEP), meropenem (MEM),
ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT),
gentamicin (GEN), doxycycline (DOX), chloramphenicol
(CHL). Each isolate was sequenced on the Illumina Hi Seq 2500
using 101 bp paired-end reads, and reads were assembled into
draft genomes using Velvet (Zerbino and Birney, 2008).
Antibiotic Resistance Gene Identification
Open reading frames in the genome assemblies were identified
using GeneMark software (Borodovsky and Lomsadze, 2011)
using the command: “gmhmmp -m <model_name> -o
<outfile> -a <contig_name_file>.” Genes were separately
annotated by three antibiotic resistance databases: ResFinder
(Zankari et al., 2012), the Comprehensive Antibiotic Resistance
Database (CARD) (McArthur et al., 2013), and Resfams (Gibson
et al., 2015). These three databases represent three different
options for cataloging resistance gene sequence data: a gene
nucleotide sequence database, a gene product amino-acid
sequence database, and a gene product amino acid Hidden
Markov Model (HMM) database.
All protein sequences from each draft genome were compared
to the ResFinder database using BLAST+ command line software
downloaded from the National Center for Biotechnology
Information (NCBI, https://blast.ncbi.nlm.nih.gov/Blast.cgi)
using the command “tblastn -query <Sequence_file> -db
<ResFinder_database_name> -culling_limit 1 -outfmt ’6 qseqid
sseqid length qlen slen qstart qend pident’ -out <out_file>.”
BLAST+ was also used to compare isolate genomes to
the CARD database, using the command “blastp -query
<protein_sequence_file> -db <CARD_name> -culling_limit
1 -outfmt ’6 qseqid sseqid length qlen slen qstart qend pident’
-out <Output_file>.” In both cases the “-culling_limit 1” flag
indicates that only the best match for each query protein will be
kept. Results were filtered to remove matches over less than 60%
of the query sequence length, and to remove duplicate matches
within the results for each genome.
Comparisons to the Resfams HMM database were made
using HMMER3 (Eddy, 2009) with the command “hmmscan
Frontiers in Microbiology | www.frontiersin.org 3 November 2016 | Volume 7 | Article 1887
Pesesky et al. Predicting Susceptibility Profiles from Genomes
–cut_ga -o /dev/null –tblast <target_out_file> –domtblast
<domain_out_file> <database_file> <protein_input_file>.”
As in previous analysis of these genomes (Pesesky et al., 2015),
genes were also compared with the Pfams (Finn et al., 2014) and
TIGRFAMs (Haft et al., 2001) HMM databases and results from
all three HMM databases were concatenated into a single file for
analysis.
Antibiotic Resistance Prediction
Antibiotic susceptibility was predicted for each isolate using
a rules-based (RB) algorithm and a Logistic Regression (LR)
algorithm with Resfams annotated genes as the inputs. The in
vitro phenotypic susceptibility results were used as the gold
standard for comparison with our GBASP results. Errors in
the GBASP were defined in relation to the in vitro results, with
major errors being a resistant prediction from the GBASP being
discrepant with an in vitro susceptible phenotype and very
major errors being a susceptible prediction from the GBASP
being discrepant with an in vitro resistant phenotype. For the
purposes of this comparison, intermediate resistance phenotypes
from the phenotypic AST were counted as resistant. The RB
algorithm was built with five separate algorithms, described
below, using custom python scripts available on (https://github.
com/mpesesky/susceptibility-prediction). For the LR algorithm,
inputs for each organism were the species, the resistance genes
as determined by resfams, and the phenotypic value determined
in vitro. We gave these inputs to the Weka 3 (Hall et al., 2009)
data mining software package with a ridge log-likelihood of 1
× 10−8 and 10 iterations to find the maximum likelihood using
the following parameters: weka.classifiers.functions.Logistic
-R 1.0E-8 -M 10. The prediction model built by logistic
regression was evaluated by leave-one-out cross validation
(Molinaro et al., 2005) where each input genome was
separately evaluated by a training set built from the other input
genomes.
β-lactam Antibiotics
Resistance against the β-lactam antibiotic class in the
Enterobacteriaceae is most frequently mediated by acquired
β-lactam cleaving enzymes active against some subset of
β-lactam antibiotics. We identified each specific β-lactamase in
a given isolate, and matched that identity to the set of β-lactam
antibiotics to which it was expected to give resistance (http://
www.lahey.org/Studies, accessed March 25th, 2014; Bush and
Jacoby, 2010). For beta-lactamases that were identified that had
less than 100% amino acid identity to a known beta-lactamase,
we assigned it to the resistance profile of the known β-lactamase
with highest sequence similarity. The expected resistance profile
for the isolate was the union of all individual β-lactamase sets,
and the predicted susceptibility profile was the inverse of the
resistance profile. For E. coli strains, the chromosomal ampC was
identified as the class C β-lactamase with less than 96% identity
to known, plasmid-borne variants of ampC. The contribution to
resistance for those genes was considered to be zero, since their
expression is known to be too low to provide clinical levels of
resistance. For the LR algorithm we used isolate species and the
presence or absence of specific β-lactamase families as input.
Ciprofloxacin
Clinical levels of resistance to fluoroquinolones in the
Enterobacteriaceae is most often mediated by mutations in
the target genes gyrA, gyrB, and parC, though subclinical levels
of resistance can be mediated by acquired enzymes, such as
qnr. We predicted susceptibility to ciprofloxacin by comparison
of the quinolone resistance determining regions (QRDR) of
gyrA (residues 68–106), parC (residues 68–106), and gyrB
(residue 426) for each isolate against the wild type. We also
identified qnr gyrase protection proteins using Resfams. For
the RB algorithm, ciprofloxacin resistance was predicted for
an isolate only if it contained two or more QRDR mutations
across all three targets, or if it contained one QRDR mutation
and a qnr gene. If the gyrA or parC genes were not completely
assembled and resistance could not be definitively determined,
than the resistance prediction was not determined (N.D.). N.D.
resistance was not counted as a major error or very major
error, but did reduce overall prediction accuracy. For the LR
algorithm, isolate species and variations in the QRDR were used
as inputs. Because of the large number of input variables in
the ciprofloxacin predictions, we tested the effect of attribute
selection on our predictive power. We used the CFS (Correlation
based Feature Selection) attribute selection algorithm to avoid
the potential for bias that a wrapper algorithm would have
with a small dataset. The attribute selection command was
weka.filters.supervised.attribute.AttributeSelection -E “weka.
attributeSelection.CfsSubsetEval” -S “weka.attributeSelection.
GreedyStepwise -T -1.7976931348623157E308 -N -1.”
Doxycycline and Chloramphenicol
For the RB algorithm we predicted isolates to be susceptible
to doxycycline only in the absence of any genes with
known tetracycline resistance phenotypes (ex. tetA). The
same metric was used for chloramphenicol, where examples
of chloramphenicol resistance genes include chloramphenicol
acetyl-transferases and chloramphenicol eﬄux pumps. The LR
algorithm for both antibiotic conditions used isolate species and
resistance gene family identity as inputs.
Gentamicin
Like the β-lactams, resistance to aminoglycoside antibiotics in
the Enterobacteriaceae is primarily mediated by specific enzymes
that affect a subset of aminoglycosides. For the RB algorithm
we determined susceptibility to gentamicin by comparing the
sequence of identified aminoglycoside resistance genes against
a database of known profiles adapted from CARD. If any of
an isolate’s aminoglycoside resistance genes had previously been
reported to provide resistance to gentamicin, we predicted the
isolate to be resistant; otherwise we predicted it to be susceptible.
For the LR algorithm we used isolate species and presence or
absence of each resistance gene family identity as inputs.
Trimethoprim-Sulfamethoxazole
Resistance to the combination therapy trimethoprim-
sulfamethoxazole in the Enterobacteriaceae is primarily mediated
by acquired resistant variants of the dihydrofolate-reductase
(DHFR) target enzyme. We are not aware of a comprehensive
Frontiers in Microbiology | www.frontiersin.org 4 November 2016 | Volume 7 | Article 1887
Pesesky et al. Predicting Susceptibility Profiles from Genomes
collection of resistant and susceptible variants of DHFR, so we
focused on identifying isolates that had multiple, unique DHFR
variants. For the RB algorithm, we predicted susceptibility to
trimethoprim-sulfamethoxazole by enumerating the unique
DHFR enzymes present within each isolate, defining unique
as having less than 95% amino acid identity to any other
DHFR in the genome. If two divergent DHFRs were present
within the same genome, that isolate was predicted to be
resistant, otherwise it was predicted to be susceptible. For the LR
algorithm we clustered all of the DHFR genes at 95% amino acid
identity using cd-hit (Fu et al., 2012) generating 20 clusters. We
used isolate species and the presence or absence of each DHFR
cluster as inputs. The sul sulfonamide resistance genes were not
detected in any isolate.
Functional Metagenomics
For functional metagenomics (Rondon et al., 2000) we utilized
protocols detailed previously (Forsberg et al., 2014). Briefly,
we sheared genomic DNA from each isolate and separated the
fragments by gel electrophoresis, purifying only the fragments
between 2 and 5 kb in size. We then barcoded and pooled
the genome fragments in to 7 pools to simplify additional
processing. The pooled fragments were next ligated them into
the expression vector pZE21 using blunt-end ligation, and
transformed into a susceptible E. coli DH10B derivative MegaX
(ThermoFisher catalog number C640003). We then plated
these recombinant E. coli libraries onto 11 Mueller-Hinton
agar plates, each containing one of the following antibiotics:
penicillin (128 µg/ml), amoxicillin (16 µg/ml), cefotaxime
(8 µg/ml), ceftazidime (16 µg/ml), meropenem (16 µg/ml),
aztreonam (8 µg/ml), gentamicin (16 µg/ml), tetracycline
(8 µg/ml), tigecycline (2 µg/ml), chloramphenicol (8 µg/ml),
and trimethoprim (8 µg/ml). Antibiotic concentrations were
determined as the empiric MIC of the host E. coli. We
next collected the surviving colonies from each plate and
isolated their plasmid DNA. These selected plasmids were then
sequenced on the Illumina HiSeq 2500 platform to identify
the antibiotic resistance gene that permitted survival. Reads
from individual genomes were separated by barcode. Rather
than using de novo assembly of the reads, as in Forsberg et al.
(2014), we aligned reads from each selection to the previously
sequenced draft genomes of each of the 78 isolates using
the default parameters of Bowtie2 (Langmead and Salzberg,
2012). Genes from those genomes that were fully covered
by reads from the selection were retrieved and annotated
using the Pfams, TIGRFAMs, and Resfams HMM databases,
using HMMER3 (Eddy, 2009) with the command “hmmscan
–cut_ga -o /dev/null –tblast <target_out_file> –domtblast
<domain_out_file> <database_file> <protein_input_file>.”
Results from all three HMM databases were concatenated into
a single file for analysis.
RESULTS
Resistance Gene Database Performance
Our first step was to compare the performance of the different
resistance gene databases in the context of susceptibility
prediction. Since this study used clinical isolates rather than well-
characterized lab strains or simulated data, there does not exist a
definitive set of resistance genes that should have been detected
by comparisons to each database. For this reason, we evaluated
each database by running the resistance genes it identified
through the RB prediction algorithm, and comparing the GBASP
results for each isolate to the phenotypic AST results (Figure 1).
Overall, the predictions based on the Resfams database were
the closest to the phenotypic results, averaging 89.0% agreement
across all 12 antibiotics. Predictions based on ResFinder were
the next closest, with 85.4% agreement, and those based on
CARD had the least agreement with the phenotypic results
at 81.0%.
The largest apparent difference between the three algorithms
was in their ability to predict resistance or susceptibility for
ciprofloxacin. For many of the isolates, insufficient information
was available from either the draft genome sequence or the
resistance database to make a resistant or susceptible call, in
which case the prediction was “not determined.” This occurred
in isolates that otherwise appeared to be susceptible, if the QRDR
of the gyrA, gyrB, or parC gene sequences could not be resolved.
“Not determined” results were not included in the overall
accuracy values given above. Because the Resfams annotations
were integrated with Pfams and TIGRfams, it was much
more likely to identify housekeeping gene sequences present
in the genome. Even discounting the ciprofloxacin results, the
RB algorithm based on Resfams annotations had the highest
agreement (88.5%) with the phenotypic AST. Agreement for the
RB algorithm based on annotations from ResFinder (85.3%) and
CARD (80.8%) also remained similar when ciprofloxacin results
were excluded.
The results for each of the three databases have
similar accuracy across the β-lactam antibiotics and
trimethoprim-sulfamethoxazole (Figure 1). For gentamicin
and chloramphenicol, Resfams and CARD both had accuracies
greater than 80%, while ResFinder was accurate for only 70.5%
of isolates. For doxycycline, Resfams had an accuracy of 94.9%,
ResFinder had an accuracy of 85.9%, and CARD had an accuracy
of 57.7%. We chose to use the Resfams annotations for all
subsequent analyses, because they led to the highest overall
agreement between the RB algorithm and phenotypic AST,
and because agreement did not drop below 75% for any of the
antibiotics tested (Figure 1).
Resistance Characteristics of the Isolates
To validate this isolate set for testing the RB and LR algorithms,
we next used Resfams to analyze the specific classes of resistance
genes present in each isolate. Many of these isolates were
multidrug resistant by the phenotypic AST, and several were
resistant to all antibiotics tested (Table 1). Though the average
number of resistance genes varied between the species in this
set, 9 of the 25 resistance gene families found in these organisms
were found in all four species, with only 5 families present in one
species exclusively (Figure 2). Previous work with these isolates
demonstrated that identical resistance genes within these gene
families were shared between different bacterial species (Pesesky
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FIGURE 1 | Prediction accuracy of the RB algorithm using the Resfams, CARD, or ResFinder databases. True Resistant: both the prediction algorithm and
the gold standard AST returned “resistant.” True Susceptible: both the prediction algorithm and gold standard AST returned “susceptible.” Major Error: the prediction
algorithm returned “resistant” while the gold standard AST returned “susceptible.” Very Major Error: the prediction algorithm returned “susceptible” while the gold
standard AST returned “resistant.” SXT, trimethoprim-sulfamethoxazole. N.D. Susceptibility could not be predicted for this antibiotic in these isolates.
et al., 2015), prompting our grouping together of the four species
considered into a single test set.
We next used functional metagenomic selections to
experimentally test whether our annotations had correctly
identified the complete set of resistance genes present in the
isolate genomes. Functional metagenomics allows multiple
genomes to be simultaneously assayed for genes that provide
a specific function. We created shotgun expression libraries in
E. coli from genomic DNA fragments of the 78 pathogenic isolate
genomes, and functionally tested these for antibiotic resistance
activities. We sequenced the selected resistance-conferring
genomic DNA fragments conferring resistance using short read
DNA sequencing on the Illumina platform and aligned the reads
to each of the 78 genomes individually (Figure 3).
No resistance genes to ciprofloxacin were identified by
functional metagenomics, since the native quinolone targets in
the expression strain provide dominant susceptibility even in the
context of exogenous expression of alternative resistant targets
(Naeem et al., 2016), and the qnr genes present in these genomes
were insufficient to provide resistance on their own. Consistent
with using gentamicin as our only aminoglycoside resistance
selection, only aminoglycoside modifying enzymes specific to
gentamicin were identified by functional metagenomics, though
aminoglycoside modifying enzymes with other specificities were
annotated in the genomes. The only genes providing resistance
to trimethoprim-sulfamethoxazole were target dihydrofolate
reductases. We anticipated that any DHFR could provide
resistance when heterologously overexpressed in a functional
metagenomic selection. We were therefore surprised to note that
a much lower proportion of E. coliDHFR genes were identified in
the functional selections than DHFR genes from the other three
pathogenic species tested.
The only antibiotic class for which we identified putative
resistance genes by functional metagenomics that were not
identified from the genome sequence were the beta-lactams. The
majority of genes in this category were ramA transcriptional
regulators which are known to confer resistance when
overexpressed in E. coli (George et al., 1995), but which are
a part of the baseline susceptibility levels of their natural
K. pneumoniae and Enterobacter sp. hosts. Similarly, the
chromosomal ampC in E. coli genome sequences were not
included as part of the final phenotypic prediction because they
are known to be natively repressed, but when overexpressed
(as in functional metagenomics) they provide broad-spectrum
resistance. However, variants of ampC known to be vector borne
and highly expressed (such as the CMY family) were counted
as resistance genes when seen in the genome sequence, though
they were phenotypically indistinguishable from chromosomal
ampC genes in the functional metagenomic assay. Accordingly,
the functional metagenomic results supported the whole genome
resistance gene identification, and did not identify any novel
genes that could have caused errors in the predictions.
Comparing the RB and LR Algorithms
With the set of resistance genes confirmed, we applied LR
machine learning and RB algorithms to predict antibiotic
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TABLE 1 | Phenotypic resistance profiles.
Isolate Species AMP CAZ CTT CFZ CRO FEP MEM CIP SXT GEN DOX CHL
PH100 E. coli 6 (R) 20 (I) 30 (S) 28 (S) 29 (S) 27 (S) 30 (S) 30 (S) 6 (R) 24 (S) 6 (R) 6 (R)
PH101-2 E. coli 6 (R) 6 (R) 31 (S) 16 (R) 6 (R) 16 (I) 33 (S) 6 (R) 6 (R) 24 (S) 6 (R) 25 (S)
PH105 E. coli 6 (R) 21 (I) 33 (S) 30 (S) 35 (S) 35 (S) 33 (S) 28 (S) 6 (R) 6 (R) 6 (R) 6 (R)
PH108 E. coli 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 17 (I) 28 (S) 6 (R) 19 (S) 24 (S) 6 (R) 17 (I)
PH114 E. coli 6 (R) 6 (R) 25 (S) 14 (R) 6 (R) 14 (R) 30 (S) 6 (R) 6 (R) 6 (R) 6 (R) 6 (R)
PH118 E. coli 6 (R) 6 (R) 31 (S) 17 (R) 6 (R) 19 (S) 32 (S) 6 (R) 17 (S) 6 (R) 6 (R) 23 (S)
PH129 E. coli 6 (R) 6 (R) 26 (S) 14 (R) 6 (R) 13 (R) 29 (S) 6 (R) 6 (R) 6 (R) 10 (R) 23 (S)
PH135 E. coli 6 (R) 6 (R) 30 (S) 23 (S) 6 (R) 21 (S) 33 (S) 26 (S) 29 (S) 25 (S) 20 (S) 27 (S)
PH141 E. coli 16 (I) 22 (I) 28 (S) 28 (S) 31 (S) 32 (S) 32 (S) 6 (R) 28 (S) 26 (S) 20 (S) 27 (S)
PH143 E. coli 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 28 (S) 6 (R) 6 (R) 6 (R) 6 (R) 25 (S)
PH151-2 E. coli 6 (R) 6 (R) 29 (S) 19 (I) 6 (R) 17 (I) 32 (S) 6 (R) 6 (R) 6 (R) 13 (I) 26 (S)
PH156-1 E. coli 6 (R) 6 (R) 26 (S) 16 (R) 9 (R) 15 (I) 30 (S) 6 (R) 6 (R) 20 (S) 19 (S) 6 (R)
PH18 E. coli 6 (R) 6 (R) 27 (S) 17 (R) 6 (R) 14 (R) 28 (S) 6 (R) 20 (S) 21 (S) 11 (I) 22 (S)
PH20 E. coli 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 27 (S) 6 (R) 6 (R) 6 (R) 11 (I) 6 (R)
PH31 E. coli 6 (R) 6 (R) 28 (S) 18 (I) 6 (R) 16 (I) 29 (S) 6 (R) 6 (R) 6 (R) 19 (S) 24 (S)
PH39 E. coli 6 (R) 21 (I) 32 (S) 31 (S) 32 (S) 35 (S) 32 (S) 26 (S) 6 (R) 23 (S) 10 (R) 25 (S)
PH51 E. coli 6 (R) 15 (R) 28 (S) 26 (S) 28 (S) 30 (S) 29 (S) 6 (R) 25 (S) 27 (S) 6 (R) 19 (S)
PH5 E. coli 6 (R) 6 (R) 28 (S) 21 (S) 12 (R) 21 (S) 29 (S) 6 (R) 6 (R) 21 (S) 12 (I) 23 (S)
PH85 E. coli 6 (R) 22 (R) 30 (S) 29 (S) 32 (S) 34 (S) 32 (S) 26 (S) 6 (R) 24 (S) 6 (R) 21 (S)
PH90 E. coli 6 (R) 6 (R) 29 (S) 23 (S) 6 (R) 24 (S) 31 (S) 6 (R) 6 (R) 22 (S) 6 (R) 25 (S)
PH92-1 E. coli 6 (R) 20 (I) 31 (S) 31 (S) 31 (S) 32 (S) 31 (S) 30 (S) 6 (R) 24 (S) 6 (R) 6 (R)
PH93 E. coli 6 (R) 20 (R) 31 (S) 29 (S) 30 (S) 32 (S) 30 (S) 27 (S) 6 (R) 24 (S) 6 (R) 6 (R)
PH94 E. coli 6 (R) 6 (R) 27 (S) 18 (I) 6 (R) 19 (S) 30 (S) 6 (R) 6 (R) 6 (R) 6 (R) 25 (S)
PH98 E. coli 6 (R) 20 (R) 28 (S) 25 (S) 29 (S) 26 (S) 29 (S) 30 (S) 6 (R) 24 (S) 6 (R) 6 (R)
WU31 E. coli 6 (R) 6 (R) 9 (R) 10 (R) 8 (R) 12 (R) 12 (R) 6 (R) 6 (R) 21 (S) 9 (R) 6 (R)
WU32 E. coli 6 (R) 6 (R) 14 (I) 14 (R) 12 (R) 17 (R) 18 (R) 6 (R) 6 (R) 17 (S) 6 (R) 6 (R)
WU33 E. coli 6 (R) 6 (R) 15 (I) 14 (R) 10 (R) 15 (R) 14 (R) 36 (S) 20 (S) 12 (R) 20 (S) 6 (R)
WU34 E. coli 6 (R) 6 (R) 12 (R) 6 (R) 6 (R) 6 (R) 15 (R) 6 (R) 6 (R) 6 (R) 6 (R) 14 (I)
WU35 E. coli 16 (I) 16 (I) 13 (I) 13 (R) 15 (R) 23 (S) 21 (I) 31 (S) 6 (R) 17 (S) 27 (S) 28 (S)
WU40 E. coli 6 (R) 11 (R) 22 (S) 21 (S) 25 (S) 32 (S) 30 (S) 34 (S) 25 (S) 21 (S) 20 (S) 24 (S)
WU43 E. coli 19 (S) 24 (S) 30 (S) 30 (S) 28 (S) 34 (S) 33 (S) 36 (S) 28 (S) 22 (S) 22 (S) 27 (S)
WU44 E. coli 6 (R) 12 (R) 21 (S) 22 (S) 26 (S) 31 (S) 30 (S) 6 (R) 25 (S) 21 (S) 23 (S) 26 (S)
WU45 E. coli 6 (R) 21 (I) 29 (S) 28 (S) 29 (S) 33 (S) 30 (S) 6 (R) 19 (S) 21 (S) 22 (S) 27 (S)
PH112-2 E. coli 6 (R) 6 (R) 13 (I) 6 (R) 6 (R) 14 (R) 14 (R) 14 (R) 6 (R) 24 (S) 9 (R) 6 (R)
PH113 E. aero 6 (R) 6 (R) 14 (I) 6 (R) 6 (R) 14 (R) 13 (R) 14 (R) 6 (R) 23 (S) 9 (R) 6 (R)
PH134 E. aero 6 (R) 6 (R) 13 (I) 6 (R) 6 (R) 12 (R) 13 (R) 15 (R) 6 (R) 6 (R) 12 (I) 6 (R)
PH138-2 E. aero 6 (R) 6 (R) 13 (I) 6 (R) 6 (R) 12 (R) 13 (R) 14 (R) 6 (R) 6 (R) 9 (R) 6 (R)
PH63 E. aero 6 (R) 6 (R) 13 (I) 6 (R) 6 (R) 12 (R) 14 (R) 14 (R) 6 (R) 6 (R) 6 (R) 6 (R)
PH84-2 E. aero 6 (R) 6 (R) 12 (R) 6 (R) 6 (R) 12 (R) 13 (R) 14 (R) 6 (R) 6 (R) 9 (R) 6 (R)
PH112-1 E. aero 6 (R) 6 (R) 26 (S) 16 (R) 6 (R) 16 (I) 29 (S) 16 (I) 6 (R) 6 (R) 16 (S) 6 (R)
PH125 E. cloa 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 9 (R) 13 (R) 6 (R) 23 (S) 6 (R) 15 (S) 9 (R)
PH158 E. cloa 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 12 (R) 14 (R) 6 (R) 6 (R) 6 (R) 10 (R) 6 (R)
PH23 E. cloa 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 10 (R) 16 (R) 6 (R) 6 (R) 6 (R) 10 (R) 6 (R)
PH24-2 E. cloa 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 9 (R) 15 (R) 6 (R) 6 (R) 6 (R) 11 (I) 6 (R)
PH82 E. cloa 6 (R) 6 (R) 22 (S) 6 (R) 6 (R) 9 (R) 29 (S) 6 (R) 6 (R) 6 (R) 10 (R) 22 (S)
WU26 E. cloa 6 (R) 6 (R) 6 (R) 6 (R) 9 (R) 13 (R) 14 (R) 6 (R) 6 (R) 6 (R) 11 (I) 17 (I)
WU27 E. cloa 6 (R) 6 (R) 13 (R) 10 (R) 12 (R) 14 (R) 14 (R) 6 (R) 6 (R) 13 (I) 6 (R) 10 (R)
WU29 E. cloa 6 (R) 6 (R) 6 (R) 6 (R) 13 (R) 10 (R) 11 (R) 29 (S) 24 (S) 21 (S) 15 (S) 21 (S)
PH102 E. cloa 6 (R) 6 (R) 10 (R) 6 (R) 6 (R) 15 (I) 27 (S) 18 (I) 6 (R) 6 (R) 6 (R) 6 (R)
PH10 K. pneu 6 (R) 6 (R) 23 (S) 6 (R) 6 (R) 11 (S) 26 (S) 6 (R) 6 (R) 6 (R) 14 (S) 11 (R)
(Continued)
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TABLE 1 | Continued
Isolate Species AMP CAZ CTT CFZ CRO FEP MEM CIP SXT GEN DOX CHL
PH11 K. pneu 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 9 (R) 12 (R) 6 (R) 6 (R) 11 (R) 14 (S) 12 (R)
PH124 K. pneu 6 (R) 6 (R) 27 (S) 15 (R) 6 (R) 17 (I) 27 (S) 10 (R) 6 (R) 25 (S) 10 (R) 16 (I)
PH12 K. pneu 6 (R) 6 (R) 9 (R) 6 (R) 6 (R) 9 (R) 12 (R) 6 (R) 6 (R) 6 (R) 14 (S) 11 (R)
PH139 K. pneu 6 (R) 6 (R) 26 (S) 6 (R) 6 (R) 15 (I) 28 (S) 6 (R) 6 (R) 6 (R) 13 (I) 6 (R)
PH150-2 K. pneu 6 (R) 6 (R) 23 (S) 6 (R) 6 (R) 10 (R) 27 (S) 6 (R) 6 (R) 24 (S) 6 (R) 6 (R)
PH152 K. pneu 6 (R) 6 (R) 24 (S) 6 (R) 6 (R) 8 (R) 26 (S) 6 (R) 6 (R) 22 (S) 6 (R) 6 (R)
PH24-1 K. pneu 6 (R) 21 (I) 28 (S) 26 (S) 28 (S) 28 (S) 29 (S) 6 (R) 6 (R) 6 (R) 14 (S) 12 (R)
PH25 K. pneu 6 (R) 6 (R) 24 (S) 6 (R) 6 (R) 12 (R) 28 (S) 6 (R) 6 (R) 6 (R) 15 (S) 14 (I)
PH28-1 K. pneu 6 (R) 23 (S) 29 (S) 27 (S) 28 (S) 31 (S) 29 (S) 30 (S) 20 (S) 22 (S) 12 (I) 20 (S)
PH38-1 K. pneu 10 (R) 23 (S) 29 (S) 26 (S) 28 (S) 31 (S) 29 (S) 30 (S) 20 (S) 23 (S) 12 (I) 19 (S)
PH40 K. pneu 9 (R) 23 (S) 30 (S) 27 (S) 29 (S) 32 (S) 30 (S) 30 (S) 21 (S) 24 (S) 13 (I) 18 (S)
PH44 K. pneu 6 (R) 6 (R) 6 (R) 6 (R) 6 (R) 9 (R) 12 (R) 6 (R) 11 (I) 6 (R) 15 (S) 23 (S)
PH49-2 K. pneu 8 (R) 24 (S) 30 (S) 28 (S) 30 (S) 32 (S) 30 (S) 29 (S) 21 (S) 23 (S) 14 (S) 18 (S)
PH72 K. pneu 6 (R) 6 (R) 17 (S) 9 (R) 6 (R) 14 (R) 25 (S) 17 (I) 6 (R) 6 (R) 9 (R) 6 (R)
PH73 K. pneu 6 (R) 24 (S) 30 (S) 28 (S) 30 (S) 31 (S) 27 (S) 29 (S) 25 (R) 22 (S) 17 (S) 25 (S)
PH88 K. pneu 6 (R) 6 (R) 24 (S) 6 (R) 6 (R) 6 (R) 26 (S) 6 (R) 20 (S) 6 (R) 10 (R) 6 (R)
PH9 K. pneu 6 (R) 18 (R) 26 (S) 23 (S) 25 (S) 24 (S) 26 (S) 6 (R) 6 (R) 6 (R) 14 (S) 11 (R)
WU10 K. pneu 6 (R) 25 (S) 31 (S) 30 (S) 32 (S) 35 (S) 32 (S) 32 (S) 26 (S) 24 (S) 18 (S) 24 (S)
WU12 K. pneu 6 (R) 6 (R) 15 (I) 6 (R) 12 (R) 16 (R) 14 (R) 6 (R) 6 (R) 22 (S) 14 (S) 6 (R)
WU18 K. pneu 6 (R) 6 (R) 15 (I) 6 (R) 11 (R) 15 (R) 14 (R) 6 (R) 6 (R) 20 (S) 14 (S) 6 (R)
WU21 K. pneu 6 (R) 6 (R) 14 (I) 6 (R) 6 (R) 6 (R) 17 (R) 6 (R) 18 (S) 22 (S) 6 (R) 19 (S)
WU23 K. pneu 6 (R) 6 (R) 13 (I) 6 (R) 6 (R) 6 (R) 13 (R) 23 (S) 6 (R) 6 (R) 10 (R) 10 (R)
WU2 K. pneu 11 (R) 25 (S) 31 (S) 30 (S) 34 (S) 33 (S) 31 (S) 36 (S) 19 (S) 21 (S) 18 (S) 24 (S)
WU3 K. pneu 6 (R) 24 (S) 30 (S) 29 (S) 32 (S) 33 (S) 30 (S) 32 (S) 24 (S) 22 (S) 19 (S) 23 (S)
WU6 K. pneu 7 (R) 22 (S) 31 (S) 29 (S) 31 (S) 34 (S) 32 (S) 33 (S) 27 (S) 24 (S) 18 (S) 23 (S)
WU7 K. pneu 6 (R) 23 (S) 29 (S) 27 (S) 30 (S) 32 (S) 30 (S) 24 (S) 12 (I) 22 (S) 19 (S) 24 (S)
WU8 K. pneu 7 (R) 23 (S) 30 (S) 29 (S) 32 (S) 34 (S) 33 (S) 24 (S) 10 (R) 26 (S) 11 (I) 6 (R)
WU9 K. pneu 10 (R) 24 (S) 30 (S) 30 (S) 32 (S) 34 (S) 30 (S) 31 (S) 23 (S) 23 (S) 19 (S) 26 (S)
Values given as zone of inhibition in mm (interpretation: R = “resistant,” S = “susceptible,” I = “intermediate”). E. aero, Enterobacter aerogenes; E. cloa, Enterobacter cloacae; K. pneu,
Klebsiella pneumoniae.
susceptibility for each isolate, using their in vitro measured
phenotypes as the gold standard (Figure 4). Our RB algorithm
had overall agreement of 89.0% with the phenotypic AST, with
an overall major error rate of 6.0% and very major error rate
of 4.9%. Agreement for individual antibiotics ranged from 79.5
to 96.2% while major error rates ranged from 0 to 15.4% and
very major error rates ranged from 0 to 11.5% (Figure 5). The
LR algorithm had a higher overall agreement of 90.8% to the
phenotypic ASTs, with amajor error rate of 2.6% and a verymajor
error rate of 6.6% (Figure 4). Individual antibiotic agreement
ranged from 80.8 to 97.4%, while major error rates ranged
from 0 to 6.4% and very major error rates ranged from 1.3 to
19.2% (Figure 6). The intra-class correlation coefficient for repeat
analysis of this data set was 1 for both algorithms, indicating
perfect reproducibility. Receiver operating characteristic (ROC)
curves for the prediction models produced by the LR algorithm
showed area under the curve values over 0.9 for half of the
antibiotics tested (Figure 7A). Though the rules-based approach
was biased to produce major errors rather than very major
errors in the case of ambiguity, the logistic regression algorithm
was not biased toward either error type. Despite this, the very
major error rates were similar between the two algorithms
[RB: 4.8%, 95% confidence interval (CI) 2.8 to 6.7%; LR:
6.6%, 95% CI 4.0 to 9.2%]. Both algorithms correctly identified
susceptible and resistant organisms for each of the 12 antibiotics
tested.
We next sought to determine if species-specific factors
contributed predictive power to the LR algorithm, or if most of
the predictive power came from species-independent variables,
such as the presence of resistance genes or mutations in
conserved enzymes, identified across species. To make this
distinction we repeated the LR predictions either excluding
species as a variable (Figure 4) or using species as the only
variable (Figure 8). While species information appeared to
have some predictive value as a variable on its own (70.7%
accurate predictions, with 18.4% major errors and 10.9% very
major errors), it was not independent from the predictive
value of the factors shared between species, as the accuracy
percentage of the complete model dropped only a small amount
when the species variable was excluded (90.1% with a major
error rate of 3.7% and a very major error rate of 6.2%,
Figure 7B).
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FIGURE 2 | Resistance gene content and sharing of the tested isolates, (A) Average number of resistance genes per genome in each of the four species
tested. (B) Network diagram demonstrating gene sharing between the four species. Each square represents a resistance gene family colored by class of antibiotic. A
line between a gene family and a species indicates that the resistance gene family was found within at least one isolate from that species. Gene families were manually
clustered based on the species in which they were found.
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FIGURE 3 | Resistance genes identified from sequence alone, and those verified functional by functional metagenomics.
FIGURE 4 | Prediction accuracy of GBASP algorithms. True Resistant: both the prediction algorithm and the gold standard AST returned “resistant.” True
Susceptible: both the prediction algorithm and gold standard AST returned “susceptible.” Major Error: the prediction algorithm returned “resistant” while the gold
standard AST returned “susceptible.” Very Major Error: the prediction algorithm returned “susceptible” while the gold standard AST returned “resistant.” SXT,
trimethoprim-sulfamethoxazole. N.D. Susceptibility could not be predicted for this antibiotic in these isolates.
Attribute Selection for Ciprofloxacin
The RB algorithm for predicting ciprofloxacin resistance was
based on the quinolone resistance-determining region (QRDR)
of the gyrA and gyrB DNA gyrase and parC topoisomerase
genes, as well as presence of the qnr quinolone resistance gene.
The oqxAB quinolone eﬄux pump genes were also detected
in Klebsiella and Enterobacter genomes, but were not used
as inputs in the RB or LR algorithms because they have not
been found to provide high levels of resistance (Hawkey and
Jones, 2009) and reduced predictive power in this set. The
large number of mutations detected in the QRDR of the total
set of isolates led to 97 input variables for the LR algorithm
for ciprofloxacin. To determine which of these variables most
affected the phenotype and to reduce the chance that the large
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FIGURE 5 | Prediction accuracy for RB algorithm alone. Percentages above bars represent percent accurate predictions and standard error for accuracy
percentage. SXT, trimethoprim-sulfamethoxazole. N.D. Susceptibility could not be predicted for this antibiotic and these isolates.
FIGURE 6 | Prediction for LR algorithm alone. Percentages above bars represent percent accurate predictions and standard error for accuracy percentage. SXT,
trimethoprim-sulfamethoxazole.
number of variables artificially inflated prediction accuracy for
ciprofloxacin, we performed attribute selection. Four variables
were shown to be most predictive by attribute selection: the
presence or absence of qnr, two mutations at serine 83 of GyrA
(to threonine and phenylalanine), and one mutation in serine
80 of ParC (to isoleucine). Predictions made using only these
four input variables showed a slightly different error profile to
predictions made from the full set of 97 input variables, but had
the same overall accuracy (92.3%).
Antibiotic Specific Sources of Error
Doxycycline was unique among the antibiotics tested in that all of
the errors for each prediction algorithm were very major errors
(Figure 4). Since no novel tetracycline resistance genes were
detected in the functional metagenomic experiment (Figure 3),
we performed repeat phenotypic AST on the erroneous isolates
with three independent testers (Table 2). All but two of these
isolates were re-classified as susceptible by all three testers, one
was classified as susceptible by two of the three testers, and the
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FIGURE 7 | ROC curves for predicting susceptible and resistant isolates for each antibiotic using the LR algorithm (A) Including and (B) not including
species as an input. Area under the curve (AUC) is given for each ROC curve.
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FIGURE 8 | Prediction accuracy for LR algorithm using species as the only input variable. AMP, ampicillin; CFZ, cefazolin; CTT, cefotetan; CAZ, ceftazidime;
CRO, ceftriaxone; FEP, cefepime; MEM, meropenem; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; GEN, gentamicin; DOX, doxycycline; CHL,
chloramphenicol.
TABLE 2 | Doxycycline re-test phenotypic profiles.
Initial ZOI Initial Interpretation ZOI A Interpretation A
WU8 11 Intermediate 10 Resistant
WU26 11 Intermediate 15 Susceptible
PH28-1 12 Intermediate 16 Susceptible
PH38-1 12 Intermediate 16 Susceptible
PH40 13 Intermediate 16 Susceptible
PH139 13 Intermediate 14 Susceptible
ZOI B Interpretation B ZOI C Interpretation C
WU8 11 Intermediate 11 Intermediate
WU26 15 Susceptible 15 Susceptible
PH28-1 17 Susceptible 17 Susceptible
PH38-1 17 Susceptible 17 Susceptible
PH40 17 Susceptible 17 Susceptible
PH139 14 Susceptible 13 Intermediate
last retained its resistant classification for all three testers. While
we cannot determine the impact that repeat testing would have
had if performed on the full matrix of isolates and antibiotics,
in this instance if we had used the repeat values rather than the
original values as our gold standard we would have achieved an
accuracy of 98.7% for doxycycline.
Mutation or loss of particular porins, in combination with
an extended spectrum beta-lactamase, can enable resistance
to fourth generation cephalosporins or even carbapenems.
This led to most of the very major errors in our beta-
lactam predictions. We could identify these porin deletions
by comparing detected porin genes between isolates previously
determined to be closely related (Pesesky et al., 2015), but we
could not identify resistance causing porin deletions without
using that phylogenetic information. Cefotetan represented a
special case as only four of the ten very major errors in predicting
susceptibility were caused by porin deletions, while the cause of
its remaining very major errors could not be determined.
DISCUSSION
The pathogens used in this study were originally selected to
represent a range of antibiotic resistance phenotypes, from
fully susceptible to pan resistant (Pesesky et al., 2015). They
also represent a high degree of intra-species genetic diversity,
particularly for the strains of E. coli (Pesesky et al., 2015), though
we found that they share many antibiotic resistance families
between species as well as between strains. Previous work with
these strains identified plasmid sequences from several of the
isolates, and we postulate that plasmids were the primary driver
of resistance gene sharing between these four species. There was
little variation between species in the performance of the GBASP
algorithms, likely as a result of this highly shared resistome.
Our set is weighted toward highly-resistant isolates compared
to an expected random set of clinical isolates, as highly
resistant isolates would be the ones where it is most important
to rapidly determine susceptibility phenotypes. Carbapenem
resistant Enterobacteriaceae, which represented 24 of our 78
isolates, have been designated one of the most urgent antibiotic
resistant threats in the U.S. today (CDC, 2013), and so our set
represents some of the most challenging pathogens clinicians
are faced with from a treatment perspective. The high degree
of accuracy of our predictions with this set shows that GBASP
will remain a viable option for rapid diagnostics even as the
prevalence of antibiotic resistance continues to increase. At the
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same time, predictions models built by the LR algorithm on this
set could potentially overestimate resistance in average clinical
isolates, and they should be retested on isolates representing a
wider range of antibiotic susceptibilities. Along with its initiative
to guide production ofWGS antimicrobial resistance diagnostics,
the FDAwill be providing representative isolate sets to be used for
diagnostic development (Sichtig, 2016).
There are several arguments against currently using GBASP
methods for initial treatment decisions. There are many
unknown parameters affecting the connection between genotype
and phenotype in bacteria, and so we cannot universally ascribe
functionality to the presence of a gene. At the same time
some variation in antibiotic susceptibility is due to factors other
than resistance gene presence or absence, such as metabolic
activity (Kaldalu et al., 2016). Additionally, GBASP methods,
unlike phenotypic methods, provide only a binary “resistant” or
“susceptible” determination, limiting the information available
to clinicians making difficult treatment decisions. PCR or
microarray methods are limited by the design of the assay
and detect only a select, pre-determined suite of resistance
determinants. Genomic methods have the additional barriers
of cost and turnaround time. In the analysis herein, the error
rates we identified for this isolate set, containing both highly
susceptible and highly resistant organisms, are too high to be
acceptable as a primary diagnostic informing treatment. Despite
all of these drawbacks the speed of genotypic diagnostics in
providing clinically relevant information will likely continue to
motivate interest and improvements from both the academic and
commercial sectors in GBASP techniques.
To maximize the benefits of GBASP for patients and
for antibiotic stewardship efforts, methods for improving
susceptibility prediction must be built into technique
development. The first question for WGS GBASP will be
which resistance database to use. For our analysis we evaluated
three curated databases already verified in the literature: a
nucleotide sequence database (ResFinder), an amino acid
sequence database (CARD), and an amino acid HMM database
(Resfams). One possible systematic reason for the relative success
of Resfams is that it is inherently hierarchical. This means
that when a resistance gene variant could not be conclusively
identified, its gene family was identified, rather than the next
closest variant. For families where different variants can have
different spectrums of resistance, such as the TEM β-lactamases,
a family-level identification led the RB-algorithm (and likely the
LR-algorithm as well) to make a more conservative prediction.
Finally, for most antibiotics tested the difference in results
between any two databases were fairly small, and it is possible
that the differences in performance were not systematic, and
were due to variations particular to this set of isolates.
Once particular genes have been identified, the next decision
point, for WGS, PCR, or microarray GBASP, is how to predict
overall organism resistance and susceptibility. We tested the two
most likely approaches: an algorithm based on current curated
scientific knowledge, our RB algorithm, which would mimic how
a human expert would approach interpreting the results, or an
approach that uses machine learning, our LR algorithm. Both
methods performed similarly in this study, but there are three
major reasons to believe that machine learning will yield a more
viable long-term approach.
First, the Enterobacteriaceae represent a best-case pathogen
family for use of the RB algorithm, since it is the bacterial family
about which antibiotic resistance has been best characterized
at a molecular and genomic level. GBASP would be useful for
many other pathogens with very different resistance patterns,
particularly Mycobacterium tuberculosis infections, as has been
suggested previously (Koser et al., 2013; Ajbani et al., 2015). The
LR algorithm, on the other hand, should perform equally well
on any bacterial pathogen for which have sufficient numbers of
characterized, banked isolates for training.
Second, as our knowledge of resistance increases or as
new resistance genes enter the pathogenic population, the RB
algorithm will need to have rules amended or added, and it
will become increasingly complex. In contrast, updating the LR
algorithm will only require adding new genes to the input list,
and the minor increases in complexity caused by additional
inputs will be balanced by the training set becoming progressively
enlarged with every new isolate tested. In theory, once the
training set becomes large enough, whole isolate genomes could
be given as inputs, potentially uncovering genomic causes
of resistance not yet discovered by conventional means. For
instance, variations in regulatory genes that affect antibiotic
target or resistance genes could have a moderate affect on
phenotype that has not yet been elucidated. If the training
set were large enough that all open reading frames could be
included as inputs in the machine learning algorithm, then such
associations could be identified from the resistance patterns.
In our hands, neither approach was computationally intensive,
although our study focused on one pre-selected pathogen family,
and computational complexity will likely become an issue if
susceptibility prediction for GBASP becomes more generally
used for more diverse pathogens.
Third, machine learning algorithms can be applied to predict
quantitative measures of resistance, such as minimum inhibitory
concentrations or zones of inhibition, rather than the binary
resistant or susceptible interpretations currently available to
genotypic diagnostics. These quantitative measures of resistance
provide a real benefit when choosing a treatment for a highly
resistant infection, and they should be integrated into GBASP
so that information can be delivered as quickly as possible. Our
set of isolates was not large enough to attempt such quantitative
predictions, but it is clear from the phenotypic range of the
isolates (Table 1) that quantitative predictions would reveal a
large amount of currently inaccessible information.
Clinical use of GBASP will need to be supported by ongoing
evaluation of pathogens for the emergence of novel resistance
genes. Functional metagenomics is a useful technique to identify
the presence of resistance genes as it can be used to assay a large
number of isolates in a single experiment (Sommer et al., 2009;
Forsberg et al., 2012). Our functional metagenomic experiments
in an E. coli host show that the resistance genes identified can
be transferred successfully from other Enterobacteriaceae species,
supporting the high proportion of resistance gene families shared
between the species and the minimal effect of species seen in the
LR model. This experiment additionally demonstrated that the
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majority of functional resistance genes in these isolates were also
identified from the genome sequence. One of the advantages of
functional metagenomics is that it can be used to identify the
spectrum of resistance within an antibiotic class. For instance,
in the aminoglycosides, only genes that provide resistance to
gentamicin were identified by functional metagenomics, though
the full set of aminoglycoside resistance genes could be seen
in the genome sequences. By performing selections on multiple
antibiotics in the same class, researchers can use functional
metagenomics to define the spectrum of a novel resistance gene
as it is identified (Forsberg et al., 2015).
The direct comparison of GBASP to phenotypic AST in
this study revealed several remaining challenges in GBASP
development. The largest biological challenge is differential
expression for the same gene in different contexts. This is
known to be important for the spectrum and resistance level of
beta-lactamases (Turton et al., 2006; Castanheira et al., 2014),
and it likely affected all of our predictions of resistance. These
expression level differences can arise either as a result of gene
location (plasmid vs. chromosomal) or regulatory sequences.
Based on the high degree of sharing between species, we
anticipate that many of the resistance genes identified in this
study were plasmid-based. Because they are mobile, plasmid-
borne genes are less likely to be part of intricate regulatory
networks, and the simple assumption that they are expressed
in sufficient quantities to provide resistance is more likely to
be accurate. On the other hand, some of the plasmids present
in these strains may be present in multiple copies, which could
also lead to variations in effectiveness in the same resistance
gene in different plasmids from different strains. Promoter
strength and regulatory sequences were not accounted for in
our algorithms because our set was too small to include those
additional variables in the LR algorithm, and the necessary rules
for the RB algorithm are not well defined. Further studies will
be necessary to determine the extent to which expression level
can be accounted for in GBASP. The fastest way to improve our
predictive power, especially formachine learning approaches, will
be to generate more genomic data with matched phenotypic AST
data.
A second, related challenge is in improving our knowledge of
the rare resistance factors that may be present in pathogens. We
observed errors in beta-lactam resistance prediction due to the
fact that changes in outer membrane porins were not included in
either the RB or LR algorithms. Similarly, there is a great diversity
in chromosomal β-lactamase genes across each of the species in
this study (such as ampC in E. coli and shv in K. pneumoniae),
and little of the functional consequence of this diversity is
understood. In general, the chromosomal ampC’s of E. coli differ
from plasmid-borne class C β-lactamases and the chromosomal
β-lactamases of K. pneumoniae or Enterobacter species in that
E. coli ampC’s do not provide resistance against cephalosporins.
This is thought to be primarily a result of promoter strength, but
it leaves open the question of whether all ampC genes can be
treated the same in GBASP or not. As a greater diversity of ampC
genes and promoters are studied, a set of rules may be identified
that define the functional effect of specific mutations, allowing
us to treat the chromosomal ampC β-lactmases similarly to how
we treated gyrA or parC genes for fluoroquinolone resistance.
Alternatively, if sufficient E. coli isolates were phenotyped and
sequenced, the results could be used throughmachine learning to
build a classification model capable of distinguishing the various
ampC genes observed in pathogenic E. coli.
The third challenge is technical: draft genome sequences
are more cost efficient to produce than complete genomes,
but they may have assembly breaks within key genes, leading
to prediction errors. The impact of this limitation was most
obvious in our ciprofloxacin predictions, where incompletely
assembled QRDR regions resulted in predictions that were not
determined (Figure 3). This type of error was more difficult
to identify when the incompletely assembled gene was part
of the accessory genome but we anticipate that some of our
very major errors in each antibiotic condition resulted from
incomplete genome assembly. Long-read sequence technologies,
such as SMRT sequencing (http://www.pacb.com) and nanopore
sequencing (nanoporetech.com) hold promise for generating
finished genomes in a single run, potentially reducing this source
of error for future datasets.
The final challenge is the choice of gold standard technique
by which to evaluate and refine predictive algorithms. We chose
to compare to disc-diffusion, because it was the technique
being used in the hospital from which the isolates were
taken. In addition, the discrete interpretation of disk diffusion
results (susceptible, intermediate, or resistant) is amenable to
comparison to GBASP. The accepted, inherent error in any in
vitro susceptibility testing method is a variance of plus or minus
one doubling dilution for the minimum inhibitory concentration
value. While we cannot evaluate the complete effect that the
variability inherent in phenotype-based AST has on our analysis,
our repeat analysis of the doxycycline testing showed that some
of the disagreement between our predictions and the in vitro
susceptibility testing were due to variable interpretations of
results for isolates near the border between susceptible and
non-susceptible. This may have been particularly true for the
doxycycline predictions because of the large number of isolates
near that border, but we hypothesize that it may have had some
effect on all of our predictions. A 4% increase in agreement
between the LR algorithm and the gold standard (such as was
seen for Doxycycline in our limited repeat testing) would have led
to a greater than 95% accuracy for 8 of the 12 antibiotics tested.
For this reason, we advocate the use of robust gold standard data
for future algorithm testing.
Our results indicate that GBASP has the potential to move
beyond an early-results supplement to phenotypic AST, and may,
in the near future, be able to fully replace methods based on
isolate growth. This can be a gradual process; GBASP can be
implemented to provide early treatment suggestions before more
definitive answers are available from phenotypic AST, similar
to how current versions of genotypic diagnostics are used. As
GBASP improves, due to larger training sets and more concrete
knowledge of the connections between resistance genotypes and
phenotypes, it can be periodically evaluated for its reliability.
While this process will require concerted effort, the benefits of
informed initial antibiotic treatments make developing GBASP a
key global public health imperative.
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